E
Exponential Biotherapies
Therapeutics to attenuate overreactions of the immune system
About Exponential Biotherapies
ExpoBio Inc. is a biotechnology company focused on developing innovative therapeutics for critically ill patients suffering from fluid overload and hemodynamic instability. The company's lead product is based on a polypeptide compound derived from the human pregnancy hormone, which targets vascular permeability to prevent tissue damage. ExpoBio's primary market includes hospitals and healthcare providers treating conditions such as Acute Kidney Injury and tissue damage after irradiation treatment. The business model revolves around advancing its product pipeline through clinical development phases, with revenue generated from partnerships, licensing agreements, and eventual product sales. Positive Phase II results have paved the way for a pivotal Phase III trial, underscoring the potential efficacy of their lead product. The management team collaborates closely with its Scientific Advisory Board and external advisors to leverage their expertise for the full development of the product pipeline. ExpoBio actively engages in new partnerships to expand its research and development capabilities.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 1993
- Headquarters
- The Hague, Netherlands
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 24.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEEDOther financing | Aug 2016 | $120K | $480K | Undisclosed | — |
| EARLY VCOther financing | Jan 2007 | $11M | $42M | Undisclosed | — |
Growth signals
Latest recorded traffic for Exponential Biotherapies is 2.4K monthly website visits, up 71.4% over the last three months. Exponential Biotherapies's team declined 50% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Exponential Biotherapies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Exponential Biotherapies’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.